

## JOSEPH LARSEN

Vice President, Strategic Portfolio Development, Venatorx Pharmaceuticals; Former Deputy Director, Division of CBRN Medical Countermeasures, Biomedical Advanced Research and Development Authority



Dr Joseph Larsen is a globally recognised leader in the area of public health preparedness with more than 20 years' experience. As Vice President, Strategic Portfolio Development at Venatorx Pharmaceuticals, Dr. Larsen is responsible for identifying new growth opportunities and translating the company's rich internal programmes toward strategic public and private partnerships. Previously, he served as Deputy Director of the Division of CBRN Medical Countermeasures within the Biomedical Advanced Research Development Authority (BARDA). In that role, he oversaw a \$2.8B fund for the late-stage development and procurement of medical products for use during public health emergencies and a \$530M annual advanced research and development fund. He also led the establishment of Project Bioshield programmes to develop vaccine and therapeutics to safe guard the American public from future Ebola virus outbreaks. Dr. Larsen was the lead for BARDA's work on combating antibiotic resistant bacteria. He previously served as Chief of the Broad Spectrum Antimicrobials programme at BARDA. In that role, he oversaw a portfolio of approximately \$1.2B in programmes that supported the development of novel antibacterial and antiviral drugs. Dr. Larsen was an American Association for the Advancement of Science (AAAS) fellow at the Department of Homeland Security. Additionally, he was a 2005 National Academy of Science Christine Mirzayan fellow with the Board of Life Sciences. He received his Ph.D. in Microbiology from the Uniformed Services University of the Health Sciences and his B.A. with honours from the University of Kansas.

## DANIEL P. GROSS

Assistant Professor, Duke University Fuqua School of Business; Faculty Research Fellow, National Bureau of Economic Research



Daniel P. Gross is an academic economist working at the nexus of strategy, economics, and public policy. His research studies the drivers and consequences of innovation, with a three-part programme examining the effects of automation on workers, firms, and labour markets; the historical origins of U.S. leadership in science and technology since the second World War; and the use of incentives and other tools in managing creative workers within organisations. His work frequently uses historical examples of industries undergoing significant technological change as a lens into the present and future. Professor Gross has a growing body of work that specifically studies crisis innovation policy and strategy, and the effects of crisis R&D efforts on post-crisis innovation, entrepreneurship, industry dynamics, regional economies, and science policy. From 2016 to 2020, he was an Assistant Professor of Business Administration at Harvard Business School. In the 2020-2021 academic year, he joined Duke's Fuqua School of Business.

## SUERIE MOON

Co-Director, Global Health Centre; Professor of Practice, The Graduate Institute, Geneva



Suerie Moon, MPA, PhD, is Co-Director of the Global Health Centre and Professor of Practice at the Graduate Institute of International and Development Studies, Geneva. She also teaches and advises doctoral students at the Harvard T.H. Chan School of Public Health as adjunct Lecturer on Global Health. Her research and teaching focus on global governance, the political economy of global health (focusing on innovation and access to medicines; outbreak preparedness and response; trade, investment and intellectual property rules; and development assistance for health), the evolution of international regimes, and innovative policies for addressing global problems. She is the author, with Wolfgang Hein, of *Informal Norms in Global Governance: Human Rights, Intellectual Property Rules, and Access to Medicines* (Routledge, 2013). She has conducted research on the policies and politics shaping innovation and access to medicines for twenty years, starting at Médecins Sans Frontières in 1999. She has served on a number of expert advisory bodies, including most recently the Board of Directors of the Drugs for Neglected Diseases initiative, WHO Fair Pricing Forum Advisory Group, Expert Advisory Group to the UN Secretary General's High-Level Panel on Access to Medicines, Proposal Review Committee of UNITAID, and US National Academies of Medicine Forum on Antimicrobial Threats. Prior to joining the Graduate Institute, she was Study Director of the Harvard-LSHTM Independent Panel on the Global Response to Ebola, and co-founded and led the Forum on Global Governance for Health, a focal point at Harvard University for research, debate and strategic convening on issues at the intersection of global governance and health. She received a BA from Yale, an MPA from Princeton, and PhD from the Harvard Kennedy School of Government.



THE  
**GRADUATE  
INSTITUTE  
GENEVA**

---

INSTITUT DE HAUTES  
ÉTUDES INTERNATIONALES  
ET DU DÉVELOPPEMENT

GRADUATE INSTITUTE  
OF INTERNATIONAL AND  
DEVELOPMENT STUDIES